Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers

Oral Oncology

Volumn 50, Issue 11, 2014, Pages 1089-1097

  Gujral, Dorothy M ^a,b   Miah, Aisha B ^a   Bodla, Shankar ^a   Richards, Thomas M ^a,b   Welsh, Liam ^a,b   Schick, Ulrike ^a,b   Powell, Ceri J ^a,b   Clark, Catharine H ^a   Bidmead, Margaret A ^a,b   Grove, Lorna ^a   Guerrero Urbano, Teresa ^a,b   Bhide, Shreerang A ^a,b   Newbold, Kate L ^a,b   Harrington, Kevin J ^a,b   Nutting, Christopher M ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Dose escalation; Hypopharynx; IMRT; Larynx

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISTANT METASTASIS; DYSPHAGIA; EAR NOSE THROAT SURGERY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HOARSENESS; HUMAN; HYPOPHARYNX CARCINOMA; HYPOPHARYNX SQUAMOUS CELL CARCINOMA; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARYNX PAIN; LARYNX SQUAMOUS CELL CARCINOMA; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OTALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PHARYNX DISEASE; PHARYNX STRICTURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; STRIDOR; TINNITUS; TREATMENT RESPONSE; XEROSTOMIA; CLINICAL TRIAL; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84928031112     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.07.018     Document Type: Article

References (37)

1. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991;324(24):1685-90.
2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8.
3. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88(13):890-9.
4. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1995;32(3):567-76.
5. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006;368(9538):843-54.
6. Waldron J, Warde P, Irish J, Pintilie M, Sellmann S, Bayley A, et al. A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. Radiother Oncol 2008;87(2):173-80.
7. Cummings B, Keane T, Pintilie M, Warde P, Waldron J, Payne D, et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 2007;85(1):7-16.
8. Leclerc M, Maingon P, Hamoir M, Dalban C, Calais G, Nuyts S, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol 2013;106(3):333-40.
9. Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A'Hern R, Miles EA, et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 2007;85(1):36-41.
10. Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, et al. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2012;82(2):539-47.
11. Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 2008;99(1):57-62. PMCID: 2453042.
12. Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CTbased delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003;69(3):227-36.
13. Humphreys M, Guerrero Urbano MT, Mubata C, Miles E, Harrington KJ, Bidmead M, et al. Assessment of a customised immobilisation system for head and neck IMRT using electronic portal imaging. Radiother Oncol 2005;77(1): 39-44.
14. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42(8):1031-9.
15. Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60(2):123-35.
16. Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations - A consensus panel summary. Int J Radiat Oncol Biol Phys 2009;73(5):1293-303.
17. Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Rhys-Evans P, et al. Electroglottographic comparison of voice outcomes in patients with advanced laryngopharyngeal cancer treated by chemoradiotherapy or total laryngectomy. Int J Radiat Oncol Biol Phys 2008;70(2):344-52.
18. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804.
19. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000;18(7):1458-64.
20. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23(6):1125-35.
21. Bensadoun RJ, Benezery K, Dassonville O, Magne N, Poissonnet G, Ramaioli A, et al. French multicenter phase III randomized study testing concurrent twicea- day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64(4):983-94.
22. Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, et al. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys 2012;82(2):524-31.
23. Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol 2012;13(2):145-53.
24. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008;26(21):3582-9.
25. Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J, et al. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol 2012;104(2):213-8.
26. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48(1):7-16.
27. Harwood AR, Hawkins NV, Rider WD, Bryce DP. Radiotherapy of early glottic cancer-I. Int J Radiat Oncol Biol Phys 1979;5(4):473-6.
28. Randall ME, Springer DJ, Raben M. T1-T2 carcinoma of the glottis: relative hypofractionation. Radiology 1991;179(2):569-71.
29. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64(1):77-82.
30. Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: Results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 2013.
31. Rades D, Fehlauer F, Sheikh-Sarraf M, Kazic N, Basic H, Poorter R, et al. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer. Head Neck 2008;30(2): 235-41.
32. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: A multivariate analysis. Int J Radiat Oncol Biol Phys 2007;68(5):1320-5.
33. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for Larynx preservation: The TREMPLIN Randomized Phase II Study. J Clin Oncol 2013;31(7):853-9.
34. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17, 346 patients. Radiother Oncol 2009;92(1):4-14.
35. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86(4):265-72.
36. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol 2011;101(3):351-5.
37. Gujral DM, Piercy D, Morden JP, Emson M, Hall E, Miah AB, et al. Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: A survey of centres participating in a national randomised controlled trial. Oral Oncol 2014;50(2):141-6.